High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizu...
High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer
About this item
Full title
Author / Creator
Furuya, Kei , Nakajima, Masao , Tsunedomi, Ryouichi , Nakagami, Yuki , Xu, Ming , Matsui, Hiroto , Tokumitsu, Yukio , Shindo, Yoshitaro , Watanabe, Yusaku , Tomochika, Shinobu , Maeda, Noriko , Iida, Michihisa , Suzuki, Nobuaki , Takeda, Shigeru , Hazama, Shoichi , Ioka, Tatsuya , Hoshii, Yoshinobu , Ueno, Tomio and Nagano, Hiroaki
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
To improve the prognosis of patients with metastatic colorectal cancer (mCRC), investigating predictive biomarkers of their prognosis and chemotherapeutic responsiveness is necessary. This study aimed to analyze the clinical significance of serum proteinase-3 (PRTN3) as a predictor for prognosis and chemosensitivity, especially to bevacizumab thera...
Alternative Titles
Full title
High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6147b1272ad342a6a9b324c9d9762daa
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6147b1272ad342a6a9b324c9d9762daa
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-024-11924-4
